Treatment response (post‐treatment score on self report and clinician‐rated scales) · somatoform disorders in adults
It is very uncertain whether new‐generation antidepressants changes treatment response (post‐treatment score on self report and… compared with placebo (very low certainty).
1 finding from 1 review
Quality of life at post‐treatment Indexed by self‐report measures of quality of life or functional disability · somatoform disorders in adults
1 finding from 1 review
Severity/intensity of MUPS (post‐treatment score on self report scales) Different self report and clinician‐rated scales (SOMS‐7, SCL‐90 Somatisation Score) · somatoform disorders in adults
1 finding from 1 review
Acceptability · somatoform disorders in adults
New‐generation antidepressants showed no clear difference in acceptability (all‐cause drop‐outs) compared with placebo (low certainty).
1 finding from 1 review
Repetition of SH at last · adults who engage in SH
Newer generation antidepressants showed no clear difference in repetition of SH at last compared with placebo (low certainty).
1 finding from 1 review
Frequency of adverse effects ‐ dizziness ( · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: dizziness compared with placebo (very low certainty).
1 finding from 1 review
Adverse event: tremor · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: tremor compared with placebo (very low certainty).
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
1 finding from 1 review
Abdominal pain · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: abdominal pains compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: headache · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: headache compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: urinary incontinence · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: urinary incontinence compared with placebo (very low certainty).
1 finding from 1 review
Somnolence · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: drowsiness compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: palpitations · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: palpitations compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects: dry mouth · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: dry mouth compared with placebo (very low certainty).
1 finding from 1 review
QoL · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months)
SoF1. Change in QoL short-term (mean Beck Depression Inventory, 0-63, lower better): this single study narratively reported that both intervention and placebo participants were less depressed at trial completion, but…
1 study · 37 participants
Very low
Repetition of SH at post‐intervention · self‐harm in adults
It is very uncertain whether newer generation antidepressants (NGAs) changes repetition of SH by post‐intervention (NGA class)№ of participants:… compared with placebo (very low certainty).
3 findings from 1 review
OR 0.59 [0.29, 1.19]
Studies not reported
Very low
OR 0.67 [0.18, 2.41]
Studies not reported
Very low
OR 0.55 [0.24, 1.29]
Studies not reported
Low
Successful discontinuation rate · participants with long‐term antidepressants for depressive disorders
1 finding from 1 review
Successful discontinuation rate · participants with long‐term antidepressants for depressive or anxiety disorders
1 finding from 1 review
Depression: meeting study criteria for depression at end of · people with stroke
It is very uncertain whether pharmacological interventions (antidepressants) changes depression: meeting study criteria for depression at end treatment… compared with placebo (very low certainty).
1 finding from 1 review
Scoring above cut‐off points for a depressive disorder at end of treatment (Analysis 1.2) · people with stroke
1 finding from 1 review